| dc.description.abstract | Two silver(I) complexes, bis{diethyl[(5-phenyl-1,3,4-oxadiazol-2-yl- N3: N4-amino) (4-
trifluoromethylphenyl)methyl]phosphonate-(tetrafluoroborato- F)}-di-silver(I) and tetrakis-{diethyl
[(5-phenyl-1,3,4-oxadiazol-2-yl- N3-amino)(4-trifluoromethylphenyl)methyl]phosphonate} silver(I)
tetrafluoroborate, were prepared starting from the diethyl[(5-phenyl-1,3,4-oxadiazol-2-yl-amino)(4-
trifluoromethylphenyl)methyl]phosphonate (1) ligand and AgBF4 salt in Ag/ligand ratios of 1/1 and
1/4, respectively. The structure, stoichiometry, and geometry of the silver complexes were fully characterized
by elemental analyses, infrared, single-crystal X-ray diffraction studies, multinuclear NMR,
and mass spectroscopies. The binuclear complex ([Ag2(1)2(BF4)2]; 2) crystallizes in the monoclinic
asymmetric space group P21/c and contains two silver atoms adopting a {AgN2F} planar trigonal
geometry, which are simultaneously bridged by two oxadiazole rings of two ligands, while the
mononuclear complex ([Ag(1)4]BF4; 3) crystallizes in the non-usual cubic space group Fd-3c in which
the silver atom binds to four distinct electronically enriched nitrogen atoms of the oxadiazole ring,
in a slightly distorted {AgN4} tetrahedral geometry. The a-aminophosphonate and the monomeric
silver complex were evaluated in vitro against MCF-7 and PANC-1 cell lines. The silver complex is
promising as a drug candidate for breast cancer and the pancreatic duct with half-maximal inhibitory
concentration (IC50) values of 8.3 1.0 and 14.4 0.6 M, respectively. Additionally, the interactions
of the ligand and the mononuclear complex with Vascular Endothelial Growth Factor Receptor-2 and
DNA were evaluated by molecular docking methods. | tr |
